

Nilofer S Azad

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11152664/nilofer-s-azad-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

13,271
citations

21
h-index

25
g-index

25
ext. papers

16,530
ext. citations

10.9
avg, IF

5.48
L-index

#	Paper	IF	Citations
25	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015 , 372, 2509-20	59.2	5560
24	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017 , 357, 409-413	41.3	3274
23	Detection of circulating tumor DNA in early- and late-stage human malignancies. <i>Science Translational Medicine</i> , 2014 , 6, 224ra24	17.5	2741
22	Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. <i>Oncotarget</i> , 2014 , 5, 587-98	3.3	299
21	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3709-14	2.2	288
20	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , 2019 , 4,	9.9	172
19	Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 1411-6	12.9	118
18	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease 2018 , 6, 35		114
17	The DNA Damaging Revolution: PARP Inhibitors and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 185-195	7.1	81
16	Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. <i>Lancet Oncology, The</i> , 2020 , 21, e135-e145	21.7	78
15	Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. <i>Cancer Immunology Research</i> , 2019 , 7, 886-895	12.5	76
14	Keratoacanthomas associated with sorafenib therapy. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 171-2	4.5	76
13	A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. <i>Clinical Cancer Research</i> , 2015 , 21, 68-76	12.9	56
12	Mutational profiling of colorectal cancers with microsatellite instability. <i>Oncotarget</i> , 2015 , 6, 42334-44	3.3	54
11	Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 214-222	2.2	53
10	Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. <i>Oncotarget</i> , 2017 , 8, 35326-35338	3.3	52
9	Epigenetic therapy for solid tumors: from bench science to clinical trials. <i>Epigenomics</i> , 2015 , 7, 215-35	4.4	46

8	Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. <i>Cancer</i> , 2008 , 112, 1726-32	6.4	39
7	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020 , 26, 4842-4851	12.9	33
6	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020 , 9, 1485-1494	4.8	25
5	Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). <i>Chinese Clinical Oncology</i> , 2020 , 9, 2	2.3	21
4	Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. <i>JCI Insight</i> , 2020 , 5,	9.9	10
3	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. <i>Clinical Epigenetics</i> , 2021 , 13, 25	7.7	3
2	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. <i>Clinical and Translational Science</i> , 2021 , 14, 954-963	4.9	2
1	. <i>Clinical Cancer Research</i> , 2009 , 15, 7749	12.9	